General Nieuws Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference EN december 19, 2018
General Nieuws Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD EN november 5, 2018
General Nieuws Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors EN oktober 29, 2018
General Nieuws Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting EN oktober 24, 2018
General Nieuws Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project EN oktober 22, 2018
General Nieuws Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME) EN september 20, 2018
General Nieuws Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1) EN september 20, 2018
General Nieuws Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria EN september 17, 2018
General Nieuws Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website EN september 10, 2018
General Nieuws ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME) EN juli 19, 2018
General Nieuws ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC EN juni 21, 2018
General Nieuws ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME) EN mei 25, 2018
General Nieuws ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018 EN mei 23, 2018
General Nieuws ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium EN mei 14, 2018
